Hypoglycemia - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 77
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H914EA52BE0EN
Leaflet:

Download PDF Leaflet

Hypoglycemia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Hypoglycemia - Pipeline Review, H2 2016’, provides an overview of the Hypoglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Hypoglycemia
  • The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects
  • The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hypoglycemia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hypoglycemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hypoglycemia Overview
Therapeutics Development
Pipeline Products for Hypoglycemia - Overview
Hypoglycemia - Therapeutics under Development by Companies
Hypoglycemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hypoglycemia - Products under Development by Companies
Hypoglycemia - Companies Involved in Therapeutics Development
Biodel Inc.
Eiger BioPharmaceuticals, Inc.
Eli Lilly and Company
Heptares Therapeutics Limited
Novartis AG
Sanofi
SkyePharma Plc
Therakind Limited
USV Limited
XERIS Pharmaceuticals, Inc.
XOMA Corporation
Zealand Pharma A/S
Zosano Pharma Corporation
Hypoglycemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Drug for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3143753 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3185643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-900018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-438544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbutaline sulphate MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-4207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News & Press Releases
Jun 13, 2016: Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
May 10, 2016: Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery
Apr 27, 2016: XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
Apr 04, 2016: XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes
Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism
Oct 13, 2015: Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia
Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand’s stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia
Jun 26, 2015: Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy
Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia
May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207
Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial
Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015
Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hypoglycemia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Hypoglycemia - Pipeline by Biodel Inc., H2 2016
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals, Inc., H2 2016
Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2016
Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H2 2016
Hypoglycemia - Pipeline by Novartis AG, H2 2016
Hypoglycemia - Pipeline by Sanofi, H2 2016
Hypoglycemia - Pipeline by SkyePharma Plc, H2 2016
Hypoglycemia - Pipeline by Therakind Limited, H2 2016
Hypoglycemia - Pipeline by USV Limited, H2 2016
Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
Hypoglycemia - Pipeline by XOMA Corporation, H2 2016
Hypoglycemia - Pipeline by Zealand Pharma A/S, H2 2016
Hypoglycemia - Pipeline by Zosano Pharma Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hypoglycemia - Dormant Projects, H2 2016
Hypoglycemia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Hypoglycemia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Biodel Inc.
Eiger BioPharmaceuticals, Inc.
Eli Lilly and Company
Heptares Therapeutics Limited
Novartis AG
Sanofi
SkyePharma Plc
Therakind Limited
USV Limited
XERIS Pharmaceuticals, Inc.
XOMA Corporation
Zealand Pharma A/S
Zosano Pharma Corporation
Skip to top


Ask Your Question

Hypoglycemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: